News
PTC Therapeutics, Inc.’s PTCT share price has dipped by 21.98%, which has investors questioning if this is right time to buy.
Capricor Therapeutics said on Monday the U.S. Food and Drug Administration (FDA) plans to convene a panel of outside experts ...
Liquidia Corporation (NASDAQ: LQDA) has recently announced a significant development in its legal dispute with United ...
Stocktwits on MSN9h
Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s OptimisticCapricor Therapeutics (CAPR) announced on Monday that it has completed a mid-cycle review meeting with the U.S. Food and Drug ...
Zacks Investment Research on MSN11h
Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains?Liquidia Technologies, Inc. (LQDA) shares rallied 13.2% in the last trading session to close at $15.83. This move can be attributable to notable volume with a higher number of shares being traded than ...
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent ...
"RetinalGenix intends to expand Institutional Review Board (IRB) approval of a clinical study to include multiple practices.
CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback